Charles S. Berkman Sells 8,215 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $30,231.20. Following the transaction, the insider now directly owns 364,131 shares in the company, valued at $1,340,002.08. This trade represents a 2.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

OmniAb Price Performance

OABI opened at $3.67 on Thursday. The company’s 50 day simple moving average is $3.49 and its 200-day simple moving average is $3.91. OmniAb, Inc. has a one year low of $3.10 and a one year high of $6.55. The stock has a market capitalization of $518.28 million, a P/E ratio of -5.92 and a beta of -0.12.

Institutional Investors Weigh In On OmniAb

Several hedge funds and other institutional investors have recently made changes to their positions in OABI. SG Americas Securities LLC boosted its holdings in OmniAb by 105.6% in the third quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock valued at $147,000 after acquiring an additional 17,901 shares during the last quarter. CWC Advisors LLC. bought a new position in shares of OmniAb in the 3rd quarter valued at about $54,000. China Universal Asset Management Co. Ltd. grew its position in shares of OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock worth $96,000 after buying an additional 8,909 shares during the period. Palumbo Wealth Management LLC raised its stake in shares of OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock worth $104,000 after buying an additional 2,744 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after buying an additional 163,038 shares during the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on OABI shares. Benchmark reissued a “buy” rating and set a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.